Search clinical trials for: Telaprevir,

Total 107 results

Louis Stokes VA Medical Center

Completed

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Hepatitis C, Chronic | Cirrhosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Hepatitis C

United States, France, Canada, Germany, Puerto Rico
Tibotec BVBA

Completed

VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.

Kidney Diseases | Hepatitis C
Janssen Infectious Diseases BVBA

Completed

A Study to Assess Safety and Pharmacokinetics of Telaprevir in Patients With Hepatic Impairment

Hepatic Impairment

Germany, Czech Republic
Vertex Pharmaceuticals Incorporated

Completed

Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

Hepatitis C

New Zealand
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and Efficacy of MP-424 to Treat Chronic Hepatitis C

Hepatitis C

Japan
Tibotec BVBA

Completed

VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram

Hepatitis C
Tibotec Pharmaceuticals, Ireland

Completed

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Hepatitis C | HIV

Belgium
Santaris Pharma A/S

Completed

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

Hepatitis C | Chronic Hepatitis C

United States
Radboud University Medical Center
Janssen, LP

Terminated

Interaction Between Paroxetine and Telaprevir (ROLEX)

Depression | Hepatitis C Infection

Netherlands
Merck Sharp & Dohme LLC

Completed

Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518)

Hepatitis C Chronic
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
Hospices Civils de Lyon

Completed

Ribavirin Bioavailability After Telaprevir Exposure

Hepatitis C

France
Janssen R&D Ireland

Completed

Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir

Hepatitis C

Germany
Vertex Pharmaceuticals Incorporated

Completed

Study of Telaprevir in Subjects With Hepatic Impairment

Hepatic Insufficiency

United States
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
Massachusetts General Hospital

Withdrawn

Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers

Viral Hepatitis C

United States
MassBiologics

Terminated

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C (MBL-HCV1)

Hepatitis C Infection

United States
GlaxoSmithKline

Completed

Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects

Thrombocytopaenia

United States
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Chronic Hepatitis C

Japan
Tibotec BVBA

Completed

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Hepatitis C | HIV | Telaprevir
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Hepatitis C
Mitsubishi Tanabe Pharma Corporation
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

Hepatitis C

Japan
Janssen-Cilag International NV

Completed

Telaprevir Open-Label Study in Co-Infected Patients

Hepatitis C, Chronic

United Kingdom, Belgium, Germany, Portugal, Russian Federation, Hungary, Ireland, Luxembourg
Hospitales Universitarios Virgen del Rocío
Bristol-Myers Squibb

Completed

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

HIV Infection | Hepatitis C, Chronic

Spain
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Hepatitis C, Chronic

United States, Australia, United Kingdom, Germany, France, Spain, Belgium, Netherlands, Canada, Brazil, Puerto Rico, Poland, Sweden, Switzerland, Israel
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Vertex Pharmaceuticals Incorporated
Tibotec BVBA

Completed

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

Hepatitis C | Opioid-Related Disorders

United States
ViiV Healthcare
Pfizer

Completed

Estimate the Effect of Telaprevir and Boceprevir on Maraviroc Pharmacokinetics in Healthy Subjects

Healthy

Belgium
Fundación Pública Andaluza Progreso y Salud

Completed

Register of Telaprevir and Boceprevir in Routine Clinical Practice

Hepatitis C

Spain
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
University of Vermont

Withdrawn

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Hepatitis C

United States
Tibotec BVBA

Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Hepatitis C, Chronic

France, United Kingdom, Sweden
University Hospital, Grenoble

Terminated

Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy (Ribatela)

C Hepatitis, Tri Therapy

France
GlaxoSmithKline

Recruiting

A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) (EAGLE-J)

Urinary Tract Infections

Japan
University of Florida
Vertex Pharmaceuticals Incorporated

Completed

Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1 (STEADFAST)

Hepatitis C, Chronic

United States
Francesco Gabrielli

Completed

Psyllium Fiber Versus Placebo in Early Treatment After STARR for Obstructed Defecation: a Double-blind RCT

Constipation | Incontinence

Italy
Weill Medical College of Cornell University
Vertex Pharmaceuticals Incorporated

Completed

Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Hepatitis C
Timothy Morgan, MD
Vertex Pharmaceuticals Incorporated

Withdrawn

Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1

Hepatitis C

United States
St Stephens Aids Trust

Completed

Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT) (CHAT)

HIV

United Kingdom
Kenneth Sherman
National Heart, Lung, and Blood Institute (NHLBI); Genentech, Inc.; Vertex Pharmaceuticals...

Completed

Viral Kinetics in HCV Clearance in Subjects With Hemophilia (HCV/Hemophil)

Hemophilia | Chronic Hepatitis C

United States
Tibotec BVBA
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate the Potential Interaction Between Telaprevir and Methadone, at Steady-State

Healthy Participants
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir

Healthy Participants

Netherlands
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1) (INSIGHT)

Chronic Hepatitis C

Australia, France, United Kingdom, Spain, Russian Federation, Brazil, Poland, Sweden
US Department of Veterans Affairs

Completed

Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence (FIRM)

Fecal Incontinence

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Hepatitis C

United States, Canada, Netherlands, Puerto Rico, Germany

Search clinical trials for: Telaprevir,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations